Cargando…

Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma

BACKGROUND: O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status has not been extensively investigated in duodenal adenocarcinoma (DA). The aim of this study was to evaluate the MGMT methylation status and examine its possible prognostic value in patients with stage III DA. METHODS: De...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Tao, Sharmab, Anup, Xie, Fei, Liu, Yanliang, Li, Kai, Wan, Weiwei, Baylin, Stephen B., Wolfgang, Christopher L., Ahuja, Nita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028050/ https://www.ncbi.nlm.nih.gov/pubmed/27643594 http://dx.doi.org/10.1371/journal.pone.0162929

Ejemplares similares

Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
por: Fu, Tao, et al.
Publicado: (2016)

MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer
por: Wang, Chuntao, et al.
Publicado: (2019)

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
por: Oliver, Jaime Antonio, et al.
Publicado: (2014)

MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients
por: Martinelli, Camila Maria da Silva, et al.
Publicado: (2016)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study
por: Guadagni, Stefano, et al.
Publicado: (2017)

Diagnostic Accuracy of Immunohistochemistry in Detecting MGMT Methylation Status in Patients with Glioma
por: Sahara, Nita, et al.
Publicado: (2021)

MTNR1B polymorphisms with CDKN2A and MGMT methylation status are associated with poor prognosis of colorectal cancer in Taiwan
por: Lee, Chia-Cheng, et al.
Publicado: (2021)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma
por: Zhang, Yang, et al.
Publicado: (2019)

A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma
por: Wang, Wen, et al.
Publicado: (2016)

MGMT Promoter Methylation and Parathyroid Carcinoma
por: Storvall, Sara, et al.
Publicado: (2019)

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM
por: Shah, Nameeta, et al.
Publicado: (2011)

Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis
por: Chan, Timothy A, et al.
Publicado: (2008)

Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
por: Siebenkäs, Cornelia, et al.
Publicado: (2017)

Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
por: Siebenkäs, Cornelia, et al.
Publicado: (2020)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme
por: Della Monica, Rosa, et al.
Publicado: (2022)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms
por: Della Monica, Rosa, et al.
Publicado: (2022)

Fast routine assessment of MGMT promoter methylation
por: Hench, Ivana Bratic, et al.
Publicado: (2020)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

TGFBI Promoter Methylation is Associated with Poor Prognosis in Lung Adenocarcinoma Patients
por: Seok, Yangki, et al.
Publicado: (2019)

71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES
por: Mamatjan, Yasin, et al.
Publicado: (2020)

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma
por: Li, Mingxiao, et al.
Publicado: (2021)

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma
por: Hsu, Chih-Yi, et al.
Publicado: (2017)

Squalene synthase predicts poor prognosis in stage I‐III colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression
por: Jiang, Huihong, et al.
Publicado: (2022)

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
por: Nguyen, Ngan, et al.
Publicado: (2021)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

The Significance of MGMT Promoter Methylation Status in Diffuse Glioma
por: Jovanović, Nikola, et al.
Publicado: (2022)

MGMT Promoter Methylation: Prognostication beyond Treatment Response
por: Ashkan, Keyoumars, et al.
Publicado: (2023)

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
por: Struve, Nina, et al.
Publicado: (2020)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma
por: Zhang, Ji, et al.
Publicado: (2020)

PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer
por: Li, Ming, et al.
Publicado: (2017)

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
por: Håvik, Annette Bentsen, et al.
Publicado: (2012)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

Aberrant Methylation of MGMT Promoter in HNSCC: A Meta-Analysis
por: Cai, Fucheng, et al.
Publicado: (2016)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a5mm8e5ap5pao65u1ruo7n1v8t